Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial-Reference-Cited by-同舟云学术

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Published:2022-05 Issue:5 Volume:9 Page:e341-e352
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Waalewijn Hylke,Chan Man K,Bollen Pauline D J,Mujuru Hilda A,Makumbi Shafic,Kekitiinwa Adeodata R,Kaudha Elizabeth,Sarfati Tatiana,Musoro Godfrey,Nanduudu Annet,Lugemwa Abbas,Amuge Pauline,Moore Cecilia L,Rojo Pablo,Giaquinto Carlo,Colbers Angela,Gibb Diana M,Ford Deborah,Turkova Anna,Burger David M

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference21 articles.

1. Update of recommendations on first- and second-line antiretroviral regimens,2019

2. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection;Bollen;Expert Opin Drug Saf,2015

3. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial;Bollen;Lancet HIV,2020

4. Waalewijn H, Mujuru HA, Amuge P, et al. Adequate dolutegravir exposure dosed BID with rifampicin in children 6 to <18 years. Conference on Retroviruses and Opportunistic Infections; March 11, 2020 (abstr 847).

5. Relative bioavailability of a dolutegravir dispersible tablet and the effects of low- and high-mineral-content water on the tablet in healthy adults;Buchanan;Clin Pharmacol Drug Dev,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study;Biomedicines;2024-09-12

2. The rollout of paediatric dolutegravir and virological outcomes among children living with HIV in Mozambique;Southern African Journal of HIV Medicine;2024-07-31

3. Paediatric antiretroviral therapy challenges with emerging integrase resistance;Current Opinion in HIV and AIDS;2024-07-05

4. Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1;Infectious Diseases and Therapy;2024-07-04

5. Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations;The Journal of Clinical Pharmacology;2024-06-19